+44 1300 500008Journal of Leukemia : Citations & Metrics Report
Articles published in Journal of Leukemia have been cited by esteemed scholars and scientists all around the world. Journal of Leukemia has got h-index 11, which means every article in Journal of Leukemia has got 11 average citations.
Following are the list of articles that have cited the articles published in Journal of Leukemia.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
Year wise published articles |
62 | 23 | 11 | 8 | 22 | 23 |
Year wise citations received |
54 | 59 | 64 | 98 | 109 | 74 |
| Journal total citations count | 618 |
| Journal impact factor | 2.11 |
| Journal 5 years impact factor | 3.71 |
| Journal cite score | 3.91 |
| Journal h-index | 11 |
| Journal h-index since 2018 | 8 |
Important citations (462)
Yusoff ym, seman za, othman n, kamaluddin nr, esa e, zulkiply na, abdullah j, zakaria z. prevalence of bcr-abl t315i mutation in malaysian patients with imatinib-resistant chronic myeloid leukemia. asian pacific journal of cancer prevention: apjcp. 2018;19(12):3317. |
|
tikhonova vv, isakov ma, misyurin va, finashutina y, kesaeva la, lyzhko na, soldatova in, kasatkina nn, misyurina en, misyurin av. tyrosine kinase inhibitor resistance in patients with chronic myeloid leukemia: a 10-year study of bcr-abl gene mutation profile in russia (2006–2016). |
|
Тихонова Ð’Ð’, ИÑаков ÐœÐ, МиÑюрин Ð’Ð, Финашутина ЮП, КеÑаева ЛÐ, Лыжко ÐÐ, Солдатова ИÐ, КаÑаткина ÐÐ, МиÑюрина ЕÐ, МиÑюрин ÐÐ’. РезиÑтентноÑÑ‚ÑŒ хроничеÑкого миелолейкоза к ингибиторам тирозинкиназ: 10 лет Ð¸Ð·ÑƒÑ‡ÐµÐ½Ð¸Ñ Ð¿Ñ€Ð¾Ñ„Ð¸Ð»Ñ Ð¼ÑƒÑ‚Ð°Ñ†Ð¸Ð¹ гена bcr-abl Ð’ РоÑÑии (2006-2016 ГГ.). КлиничеÑÐºÐ°Ñ Ð¾Ð½ÐºÐ¾Ð³ÐµÐ¼Ð°Ñ‚Ð¾Ð»Ð¾Ð³Ð¸Ñ. Фундаментальные иÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ð¸ клиничеÑÐºÐ°Ñ Ð¿Ñ€Ð°ÐºÑ‚Ð¸ÐºÐ°. 2018;11(3). |
|
Ursan id, jiang r, pickard em, lee ta, ng d, pickard as. emergence of bcr-abl kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors. journal of managed care & specialty pharmacy. 2015 feb;21(2):114-22. |
|
Al-anazi ka. myelodysplastic disorders, 5q-syndrome. myelodysplastic syndromes. 2016 sep 7:95. |
|
Robak t. editor note. j leuk. 2016;4:e118. |
|
Ala n, jcna a, dsb n, tila a, eta k. research & reviews: journal of medical and health sciences. |
|
Ala n, jcna a, dsb n, tila a, eta k. research & reviews: journal of medical and health sciences. |
|
Ala n, jcna a, dsb n, tila a, eta k. research & reviews: journal of medical and health sciences. |
|
Yasala ak, khan t. research & reviews: journal of medical and health sciences. |
|
Ala n, jcna a, dsb n, tila a, eta k. research & reviews: journal of medical and health sciences. |
|
Ala n, jcna a, dsb n, tila a, eta k. research & reviews: journal of medical and health sciences. |
|
Ala n, jcna a, dsb n, tila a, eta k. research & reviews: journal of medical and health sciences. |
|
Lnt and cancer risk assessment: its flawed foundations part 1: radiation and leukemia: where lnt began |
|
Thyroid cancer following childhood low-dose radiation exposure: a pooled analysis of nine cohorts |
|
Radiological weapons |
|
Zakharova ev. chemotherapy for renal al amyloidosis: treatment results and outcomes in 49 patients from a single center. significance.3:15-6. |
|
Ala n, jcna a, dsb n, tila a, eta k. research & reviews: journal of medical and health sciences. |
|
Natural killer cell-based immunotherapy for acute myeloid leukemia |
|
Umbilical cord preservation- a review |
|